Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lexapro Clear all
Completed Phase 4 Interventional

Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

NCT00296790
View directory record Official record
Conditions
Insomnia
Interventions
zolpidem tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 12, 2007 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Escitalopram (Lexapro) for the Treatment of Postpartum Depression

NCT00833469
View directory record Official record
Conditions
Postpartum Depression
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 23, 2026, 6:09 AM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Results available

Drug Therapy to Treat Minor Depression

NCT00048815
View directory record Official record
Conditions
Depression
Interventions
Citalopram, St. John's Wort, Placebos
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Early Phase 1 Interventional

Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer

NCT01725048
View directory record Official record
Conditions
Major Depressive Disorder, Neoplasms
Interventions
Mirtazapine, Citalopram
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome

NCT00149825
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, CBTI, CTRL
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 23, 2026, 6:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome of Depression & Treatment Response to Citalopram

NCT02330068
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
citalopram
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 23, 2026, 6:09 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression

NCT00824044
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Escitalopram
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Antidepressant Treatment at an Inner City Asthma Clinic

NCT01324700
View directory record Official record
Conditions
Depression, Asthma
Interventions
High severity group: Escitalopram, High severity group: Placebo, Low severity group: Escitalopram, Low severity group: Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

NCT01838876
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
88
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 23, 2026, 6:09 AM EDT
Terminated Phase 3 Interventional Results available

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

NCT00642694
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, Ramelteon, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional

Effects Of Antidepressants On Sexual Functioning In Adults

NCT00051272
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 23, 2026, 6:09 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111539
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Blinded capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Research Evaluating the Value of Augmenting Medication With Psychotherapy

NCT00057551
View directory record Official record
Conditions
Depression, Depressive Disorder
Interventions
Brief Supportive Psychotherapy, CBASP, Medication Only
Behavioral · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Tucson, Arizona • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 23, 2026, 6:09 AM EDT
Not listed Phase 3 Interventional

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

NCT00239954
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
18 Years to 80 Years
Timeline
Started 2005
U.S. locations
4
States / cities
Los Alamitos, California • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

SSRI Effects on Depression and Immunity in HIV/AIDS

NCT02620150
View directory record Official record
Conditions
Depression, HIV, AIDS
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of Medication With or Without Psychotherapy for Complicated Grief

NCT01179568
View directory record Official record
Conditions
Complicated Grief, Bereavement
Interventions
Citalopram, Complicated Grief Treatment, Placebo
Drug · Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg

NCT00648570
View directory record Official record
Conditions
Healthy
Interventions
Escitalopram Oxalate Tablets 20 mg, Lexapro® Tablets (20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

NCT00252356
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS

NCT00887679
View directory record Official record
Conditions
Anxiety Disorders, HIV Infections
Interventions
Escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 23, 2026, 6:09 AM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Serotonin in Acute and Subacute MDMA Effects

NCT00838305
View directory record Official record
Conditions
MDMA Mechanism of Action
Interventions
MDMA and citalopram, Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 23, 2026, 6:09 AM EDT